Evidence map›Paper›PMID 42769546›Full record

ArticleMedComm2026

Tripterine Liposome Exerts Antitumor and Immunomodulatory Effects in Pancreatic Ductal Adenocarcinoma.

Lirui Tang, Yi Lin, Xueqin Jiang, Xiaohe Tian, Giuseppe Battaglia, Yuquan Wei, Wenshuang Wu, Xuemei He, Xiawei Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lirui Tang *Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China.
Yi Lin *Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China.
Xueqin Jiang *Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.
Xiaohe TianDepartment of Radiology Functional and Molecular Imaging Key Laboratory of Sichuan Province Huaxi MR Research Centre (HMRRC) Chengdu China.ORCID https://orcid.org/0000-0002-6513-6422
Giuseppe BattagliaInstitute for Bioengineering of Catalonia (IBEC) The Barcelona Institute of Science and Technology Barcelona Spain.
Yuquan WeiLaboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China.
Wenshuang WuDivision of Thyroid Surgery Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease Frontiers Science Center for Disease-related Molecular Network West China Hospital Sichuan University Chengdu China.
Xuemei HeLaboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China.
Xiawei WeiLaboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly aggressive phenotype and limited therapeutic options, primarily attributable to diagnostic delays and intrinsic chemotherapy resistance, thereby underscoring the critical need for the development of more effective therapeutic strategies. Tripterine (TP) is a natural compound with potent antitumor activity, but has shown limited clinical use due to its multi-organ toxicity. Here, we overcame this limitation by formulating TP into liposomes (TP-lipo). We evaluated the therapeutic potential of TP-lipo showing that TP-lipo exhibited antitumor activity in vitro (murine

Indexed as

liposomepancreatic ductal adenocarcinomatripterinetumor microenvironment

Identifiers

PMID42769546
PMCPMC13591019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.